<DOC>
	<DOCNO>NCT02333643</DOCNO>
	<brief_summary>A phase 2 , randomize , vehicle-controlled , double-blind study ass efficacy , safety pharmacodynamics ( PD ) topically apply CLS003 otherwise healthy patient cutaneous wart .</brief_summary>
	<brief_title>A Phase 2 Efficacy Study CLS003 ICVT Subjects With Cutaneous Warts .</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<criteria>absence evidence active chronic disease ; Free clinical significant systemic dermatologic disorder , , opinion investigator , interfere study result increase risk Adverse Events ; Have least 2 ( nonsubungual ) common wart least 2 plantar wart nongenital , nonfacial skin Any clinically significant abnormality opinion investigator would interfere study objective compromise subject safety ; For woman : positive pregnancy test and/or nursing screen woman plan become pregnant breastfeeding ; A positive test drug abuse screening ; History alcohol illicit drug abuse ( alcohol abuse define alcohol consumption &gt; 28 units/week ) ; Positive test result Hepatitis B , Hepatitis C HIV ; Have use salicylic acid overthecounter wartremoving product treatment area within 30 day prior start study cryotherapy within 60 day start study ; Have require systemic intake immunosuppressive immunomodulatory medication ( include oral parenteral corticosteroid ) within 30 day prior enrollment course study . Routine use inhale intranasal corticosteroid study allow ; Have know sensitivity investigational product ingredient Clinically relevant abnormal laboratory result , ECG , vital sign , physical finding screen ; Participation investigational drug device study within 3 month prior screen 4 time past year ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>